In the article on In vitro Effects of the BH3 Mimetic, (−)-Gossypol, on Head and Neck Squamous Cell Carcinoma Cells in the November 15, 2004, issue of Clinical Cancer Research, the following disclosure was omitted:

Ascenta Therapeutics Inc. has licensed certain technologies related to (−)-gossypol from the University of Michigan. One of the co-authors in this publication, Shaomeng Wang, owns equity in Ascenta Therapeutics and is also a consultant to Ascenta Therapeutics Inc. In addition, the University of Michigan also owns equity in Ascenta Therapeutics Inc.

Oliver CL, Bauer JA, Wolter KG, et al. In vitro effects of the BH3 mimetic, (−)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 2004;10:7757–63.